New targeted drug trial opens for patients with Hard-to-Treat neuroendocrine cancers

NCT ID NCT07129252

Recruiting now Disease control Sponsor: Crinetics Pharmaceuticals Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 3 times

Summary

This study tests a new drug called CRN09682 in people with progressive metastatic neuroendocrine neoplasms and other solid tumors that have a specific marker (SST2). The trial has two phases: first, finding the safest dose, then testing that dose in more patients. About 150 participants will be enrolled to see if the drug is safe and can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CRN09682 (a drug given intravenously that targets somatostatin receptor type 2 on tumor cells)
What this could lead to: If successful, this could lead to a new treatment option for people with certain neuroendocrine and other solid tumors that have stopped responding to standard therapies.
What could go wrong: This is an early-phase trial (Phase 1/2) with only 150 participants, so the drug may not prove effective or safe in larger groups. Side effects, including severe ones, are possible and being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm Neoplasm Metastasis neuroendocrine carcinoma neuroendocrine neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROENDOCRINE NEOPLASM NEUROENDOCRINE TUMORS SST2-POSITIVE NEUROENDOCRINE NEOPLASMS

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Crinetics Study Site
RECRUITING

Phoenix, Arizona, 85054, United States
Crinetics Study Site
RECRUITING

Duarte, California, 91010, United States
Crinetics Study Site
RECRUITING

Newport Beach, California, 92663, United States
Crinetics Study Site
RECRUITING

Orange, California, 92868, United States
Crinetics Study Site
RECRUITING

San Francisco, California, 60637, United States
Crinetics Study Site
RECRUITING

Aurora, Colorado, 80045, United States
Crinetics Study Site
RECRUITING

Denver, Colorado, 80218, United States
Crinetics Study Site
RECRUITING

New Haven, Connecticut, 48201, United States
Crinetics Study Site
RECRUITING

Atlanta, Georgia, 30322, United States
Crinetics Study Site
RECRUITING

Lexington, Kentucky, 40536, United States
Crinetics Study Site
RECRUITING

Metairie, Louisiana, 70006, United States
Crinetics Study Site
RECRUITING

Detroit, Michigan, 48201, United States
Crinetics Study Site
RECRUITING

Grand Rapids, Michigan, 49503, United States
Crinetics Study Site
RECRUITING

Rochester, Minnesota, 53905, United States
Crinetics Study Site
RECRUITING

New York, New York, 10016, United States
Crinetics Study Site
RECRUITING

Philadelphia, Pennsylvania, 19104, United States
Crinetics Study Site
RECRUITING

Philadelphia, Pennsylvania, 19111, United States
Crinetics Study Site
RECRUITING

Austin, Texas, 78758, United States
Crinetics Study Site
RECRUITING

Houston, Texas, 70030, United States
Crinetics Study Site
RECRUITING

Irving, Texas, 75039, United States
Crinetics Study Site
RECRUITING

Salt Lake City, Utah, 84112, United States
Crinetics Study Site
RECRUITING

Charlottesville, Virginia, 22908, United States
Crinetics Study Site
RECRUITING

Fairfax, Virginia, 22031, United States
Crinetics Study Site
RECRUITING

Barcelona, 08023, Spain
Crinetics Study Site
RECRUITING

Barcelona, 08035, Spain
Crinetics Study Site
RECRUITING

Madrid, 28040, Spain
Crinetics Study Site
RECRUITING

Madrid, 28041, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.